The industry’s inability to make products efficiently and at scale is due to the complexity of the supply chain, panelists said at the Cell & Gene Meeting on the Mesa.
The Germany-based CDMO has named its Cuxhaven facility a Center of Excellence for Analytical Services, expanding GMP lab capacity to support advanced therapy and biologics programs.
The UK-based CDMO acquired an FDA-approved cell and gene therapy site in Durham, North Carolina, adding commercial-scale viral vector production and fill-finish capacity to its U.S. network.
Join us for a high-impact roundtable where industry leaders explore how digital transformation is revolutionizing the manufacturing of new modalities—unlocking the full potential of personalized, scalable, and rapidly delivered therapies.
